TezacaftorMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/kaftrio-75-mg-50-mg-100-mg-comprime-pellicule-kalydeco-150-mg-comprime-pellicule
2024
false
false
false
France
French
cystic fibrosis
guidelines for drug use
continuity of patient care
drug therapy, combination
administration, oral
ivacaftor, tezacaftor and elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
elexacaftor
adult
adolescent
ivacaftor
trikafta
drug combinations
drug information

---
https://www.has-sante.fr/jcms/p_3552796/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-enfant-6-ans
2024
false
false
false
France
drug therapy, combination
drug combinations
treatment outcome
insurance, health, reimbursement
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508
ivacaftor, tezacaftor and elexacaftor
ivacaftor
administration, oral
evaluation of the transparency committee
elexacaftor
child
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3517566/fr/kaftrio-ivacaftor/tezacaftor/elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-de-2-ans-a-moins-de-6-ans
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
drug combinations
drug therapy, combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
administration, oral
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://www.has-sante.fr/jcms/p_3460573/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacafto-en-association-avec-kalydeco-mucoviscidose-enfant-6-ans
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug therapy, combination
drug combinations
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
ivacaftor
tezacaftor
guidelines for drug use
evaluation of the transparency committee
child
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3327002/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacafto-en-association-avec-kalydeco-mucoviscidose
https://www.has-sante.fr/jcms/p_3327010/fr/decision-n-2022-0178/dp/sem-du-28-mars-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-kaftrio
2022
false
false
false
France
drug therapy, combination
drug combinations
administration, oral
ivacaftor, tezacaftor and elexacaftor
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
ivacaftor
tablets
legislation
guidelines for drug use
child
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
ivacaftor
tezacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
continuity of patient care
forms
professional role
evaluation of the transparency committee
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3343179/fr/kaftrio-elexacaftor/-ivacaftor/-tezacaftor-mucoviscidose
2022
false
false
false
France
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
elexacaftor
insurance, health, reimbursement
treatment outcome
administration, oral
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
drug combinations
ivacaftor, tezacaftor and elexacaftor
CFTR delta F508
evaluation of the transparency committee
tezacaftor
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3343185/fr/kaftrio-elexacaftor/-ivacaftor/-tezacaftor-mucoviscidose
2022
false
false
false
France
French
evaluation of the transparency committee
tezacaftor
registries
cystic fibrosis
tezacaftor
Cystic fibrosis
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3302605/fr/kalydeco-150-mg-ivacaftor
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug therapy, combination
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
elexacaftor
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
administration, oral
cystic fibrosis
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3282752/fr/symkevi-100-mg/150-mg-ivacaftor/-tezacaftor-mucoviscidose-6-ans
2021
false
false
false
France
evaluation of the transparency committee
aminophenols
drug combinations
indoles
quinolones
benzodioxoles
child
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
cystic fibrosis
tezacaftor, ivacaftor drug combination
tezacaftor
ivacaftor
ivacaftor and tezacaftor
drug therapy, combination
treatment outcome
insurance, health, reimbursement
administration, oral

---
https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi
2021
false
false
false
Netherlands
French
English
drug approval
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
tezacaftor, ivacaftor drug combination
tezacaftor
tezacaftor
ivacaftor
ivacaftor
administration, oral
ivacaftor and tezacaftor
Chloride Channel Agonists
Chloride Channel Agonists
cystic fibrosis
drug interactions
pregnancy
breast feeding
child
adolescent
adult
orphan drug production
drug monitoring
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aged
drug evaluation, preclinical
aminophenols
indoles
quinolones
benzodioxoles
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones

---
https://www.has-sante.fr/jcms/p_3303740/fr/kaftrio-75-mg/50-mg/100-mg-elexacaftor/-ivacaftor/-tezacaftor
2021
false
false
false
France
CFTR delta F508
elexacaftor
ivacaftor
tezacaftor
drug combinations
treatment outcome
insurance, health, reimbursement
administration, oral
cystic fibrosis
cystic fibrosis
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
ivacaftor, tezacaftor and elexacaftor
evaluation of the transparency committee
elexacaftor, ivacaftor, tezacaftor drug combination

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines

---
https://www.has-sante.fr/jcms/p_3184439/fr/symkevi-/-kalydeco
2020
false
false
false
France
drug combinations
administration, oral
insurance, health, reimbursement
ivacaftor and tezacaftor
ivacaftor
cystic fibrosis
adolescent
Product containing only ivacaftor and tezacaftor in oral dose form (medicinal product form)
tezacaftor
CFTR delta F508
treatment outcome
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
tezacaftor, ivacaftor drug combination
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles

---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00402
2018
false
false
false
Canada
French
drug information
administration, oral
drug approval
canada
ivacaftor and tezacaftor
drug combinations
tezacaftor
tezacaftor
ivacaftor
ivacaftor
cystic fibrosis
adolescent
adult
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
treatment outcome
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones
tezacaftor, ivacaftor drug combination

---